Market capitalization | $217.37m |
Enterprise Value | $-139.44m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.98 |
P/B ratio (TTM) P/B ratio | 0.63 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-101.87m |
Free Cash Flow (TTM) Free Cash Flow | $-70.45m |
Cash position | $358.16m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
7 Analysts have issued a Terns Pharmaceuticals Inc forecast:
7 Analysts have issued a Terns Pharmaceuticals Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.90 -0.90 |
2%
2%
|
|
EBITDA | -101 -101 |
1%
1%
|
EBIT (Operating Income) EBIT | -102 -102 |
1%
1%
|
Net Profit | -89 -89 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Head office | United States |
CEO | Amy Burroughs |
Employees | 59 |
Founded | 2017 |
Website | www.ternspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.